FMXIN002 in Patients at Risk of Anaphylaxis
Study sponsor: Nasus Pharma
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-06-12Estimated
Enrollment · participants30Estimated
Source updated2025-07-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.